Why the study?
18F-FDG PET imaging in cardiac angiosarcoma is challenging due to myocardial glucose uptake, whereas measuring cell proliferation with 18F-FLT PET/CT could exploit the higher proliferation rate of cardiac tumours.
Can 18F-FLT PET/CT be used to effectively image and delineate cardiac angiosarcoma?
Can 18F-FLT PET/CT be used to effectively image and delineate cardiac angiosarcoma?
18F-FLT PET/CT may be a useful imaging modality for delineating cardiac angiosarcoma by exploiting its higher cell proliferation rate compared to normal myocardium, overcoming the challenges of FDG-PET.
Answers are grounded in this paper and cite their sources.
May aid cardiac angiosarcoma delineation; leaves open prospective validation of accuracy and utility.
Primary cardiac angiosarcoma, the most common primary cardiac sarcoma has an incidence ranging from 0.001% to 0.028% in autopsy reports with around 200 cases reported in literature. Since a diagnosis of cardiac angiosarcoma portends a poor prognosis, it is vital to ascertain the precise extent of the lesions for follow-up. Imaging with positron emission tomography (PET) tracer 2-deoxy-2-[ 18 F]-fluoro-D-glucose in cardiac angiosarcoma is challenging as myocardium takes up glucose and delineation of tumour becomes difficult. Cell proliferation rate in normal cardiac muscular tissue is low whereas cardiac tumours display a higher proliferation rate. This aspect could be exploited by use of 3′-deoxy-3′[ (18) F]-fluorothymidine positron emission tomography ( 18 F-FLT PET/CT] in cardiac tumours where the cell proliferation could be measured. Herein, we imaged an index case of cardiac angiosarcoma using 18 F-FLT PET/CT and report the findings.
No takes yet. Share an insight, caveat, or question.
Kairemo et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: